Compare PLAB & IMNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PLAB | IMNM |
|---|---|---|
| Founded | 1969 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Semiconductors | Medicinal Chemicals and Botanical Products |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.0B | 2.2B |
| IPO Year | 1987 | 2020 |
| Metric | PLAB | IMNM |
|---|---|---|
| Price | $34.73 | $19.99 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $43.50 | $31.44 |
| AVG Volume (30 Days) | 2.2M | ★ 3.1M |
| Earning Date | 02-25-2026 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 9.09 | N/A |
| EPS | ★ 2.28 | N/A |
| Revenue | ★ $849,294,000.00 | $9,679,000.00 |
| Revenue This Year | $7.61 | N/A |
| Revenue Next Year | $7.50 | $11.53 |
| P/E Ratio | $15.44 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $16.46 | $5.15 |
| 52 Week High | $39.80 | $25.30 |
| Indicator | PLAB | IMNM |
|---|---|---|
| Relative Strength Index (RSI) | 62.92 | 49.20 |
| Support Level | $31.93 | $19.15 |
| Resistance Level | $35.77 | $21.67 |
| Average True Range (ATR) | 1.35 | 1.20 |
| MACD | -0.28 | -0.36 |
| Stochastic Oscillator | 75.13 | 24.85 |
Photronics Inc is a U.S.-based company principally engaged in the manufacturing of photomasks, which are high-precision photographic quartz or glass plates containing microscopic images of electronic circuits. Photomasks are a key element in the manufacture of integrated circuits (ICs) and flat-panel displays (FPDs) and are used as masters to transfer circuit patterns onto semiconductor wafers and FPD substrates during fabrication, as well as to a lesser extent, other types of electrical and optical components. The Company has manufacturing facilities in Taiwan, China, South Korea, the United States, and Europe, and generates revenue globally, with Taiwan contributing the majority of total revenue.
Immunome Inc is a biopharmaceutical company. It is engaged in utilizing a proprietary human memory B cell platform to discover and develop first-in-class antibody therapeutics designed to change the way diseases are currently being treated. The objective of the company is to establish a broad pipeline of preclinical and clinical assets which it can efficiently develop through successive value inflection points. The company's primary focus areas are oncology and infectious diseases, including COVID-19. It operates in the U.S. Its current pipelines comprise IM-1021, a fibroblast activation protein (FAP), and others.